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1105-78 Angiogenlc Growth Factors Expression of In-Vivo 
Human Aortic Endothelial Cells Within Gas-Plasma 
Treated Implants 
Oscar C. Munoz, Jodie Polan, Nilesh Goswami, Mauli Agrawal, Staven Bailey, University 
of Texas Health Science Center at San Antonio, San Antonio, Texas. 
Background: Ischemia induces expression of angiog6nic proteins such as Vascular 
Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF). VEGF is 
essential in initiating endothelial migration, stimulating the release of other growth factors 
and inducing neovasculadzation (angiogenesis). We previously demonstrated in our lab- 
oratory that gas-plasma treated bioresorbable poly-D, L-lectide acid implants seeded 
with Human aortic endothelial cells (HAECs) promote in vivo angiogenesis in athymic 
nude mouse model. 
Materlala and Methods: HAECs seeded at a density of 3x104 were incubated in gas- 
plasma treated implants for 6 days. Implants were positioned in the omentum of 17-22 
grn nude (N= 115) grouped into shams (n=7), both control and treated implants with and 
without HAECs (n=27 per group). Animals were sacrificed at days 12, 18, 24 and 72. 
Implants, omentum and adjacent skin were sampled. Laser confecal micrographs were 
used to determine the apparent surface areas per endothelial cell expressing either fluo- 
rescent VEGF conjugated to Alexa 546 (CY5) or bFGF using (PeproTech) mouse antihu- 
man monoclonal antibody conjugated to IgG-CY3 (Sigma; EXC552/EM565). Data was 
analyzed using ImagePro, EXCEL and Sigma Plot. Both T test and linear regressions 
were performed. 
Results: VEGF and bFGF were found in endothelial cells located in and around the 
implant. The surface area of HAECs expressing VEGF within Control and Treated 
implants were significantly different : 92 ± 41.9 vs. 221± 83.5 (arbitrary units), p=0.0001 
and r2=0.00714. Similar results were found for HAECs expressing bFGF. 
Conclusions: VEGF and bFGF enhancement of transplanted HAECs in gas-plasma 
treated implants provide a cell-based mechanism of enhanced angiogenesis in our in 
vivo nude mouse model 
ABSTRACTS - Hypertension, Vascular Disease, and Prevention JACC March 6, 2002 
POSTER SESSION 
1106 Pharmacology of Antithrombotic and 
Antiplatelet Agents 
Monday, March 18, 2002, Noon-2:00 p.m. 
Georgia World Congress Center, Hall G 
Presentation Hour: Noon-l:00 p.m. 
1106-79 Enoxaparin Versus Heparin in Patients Receiving 
Ept l f lbat ide  
Daniel D. Gretler, Leese 1". Phillip, Kealy A. Jennifer, Kitt M. Michael, COR Therapeutics 
/nc, South San Francisco, California, Quinti/es, Inc., Lenexa, Kentucky. 
GPIIb/llla inhibitor trials have been conducted with the coadministration of unfrectionatad 
heparin (UFH). However, low molecular weight hepadns (LMWH) are being used 
increasingly in clinical practice. To examine the appropriateness of substituting enox- 
apadn (Eno) for UFH in patients treated with aptifibattde (Ept), the PK and PD properties 
of Ept were examined with Eno versus UFH in a randomized, two-way crossover study in 
14 men and women ages 45 to 60. Drug regimens were administered for 48 h as follows: 
Ept 180 tlg/kg iv bolus and 2 pg/kg-min infusion plus either UFH 5000 IU IV bolus and 
1000 U/h infusion or Eno 1 mg/kg sc q12h. 
Results: Figure 1 depicts Ept plasma concentrations and platelet aggregation over time. 
Ept plasma concentrations decreased transiently between 1 and 4 hours, which is pre- 
vented by the addition of a second 180 pg/kg bolus, as used in the ESPRIT trial. Levels 
were virtually identical regardless of the administration of Eno versus UFH with steady- 
state mean±SD values (1610±229 ng/mL versus 1640±227 ng/mL; p=0.408). Ex vivo 
platelet aggregation induced by 20 pM ADP was almost completely inhibited at all time 
points with both regimens (2±4% and 3¢6% at staady-state; p=0.937). Lastly, estimates 
for mean±SE IC50 for Ept were very similar regardless of Eno versus UFH administration 
( 171± 16 and 174±16 ng/mL, respectively). 
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Conclusions: The substitution of Eno for UFH does not affect the plasma concentrations 
of Ept or the level of platelet aggregation inhibition achieved at any time point. 
1106-80 A Prospective and Randomized Compar i son  o f  Low 
Molecular Weight Heparln and Unfractioned Heparln in 
Chronically Anticoagulated Patients Prior to Cardiac 
Catheter i zat ion  
Hevder Omran, Chdstoph Hammerstingl, Harald Schmidt, Bemdt L~dedtz, University of 
Bonn, Bonn, Germany 
Background: It is recommended to discontinue oral anticoagulation (OAC) prior to car- 
diac cathatedzation in chronically anticoagulated patients (pts). To prevent thromboem- 
bolic complications pts should receive intermittent herapy with unfractionatad heparin 
(UH). Low molecular weight heparins (LMWH) have a higher bioavailability and more 
predictive anticoagulatory effect than UH. The aim of this prospective randomized trial 
was to compare the effectiveness of enoxaparin and UH for achieving anticoagulation 
prior to cardiac catheterization in OAC pts. 
Methods: Consecutive chronically anticoagulated pts with either atrial fibrillation and / or 
mechanical heart valves were included in the study. Pts were randomized to receive 
either weight adapted enoxaparin s.c. 2 times per day or weight adapted intravenous UH. 
Cardiac procedures were performed at an INR < 1.5. The activated PTr (effective: 1.5 to 
2.5 x the control value) and anti-Xa activity was measured daily (effective: 0.5-1.0 IU/ml). 
The primary endpoint of the study was the time (days) until effective anticoagulation was 
achieved under both treatment strategies. The secondary endpoint was the percent of 
days of ineffective treatment. 
Results: 27 pts were treated with enoxaparin and 26 patients with UH. The groups did not 
differ for age, sex, left ventricular ejection fraction and distribution for the indication of 
OAC. The time until effective anticoagulation was achieved was significantly shorter in 
the enoxaparin group as compared to the UH group (1.3 ± 0.6 versus 3.0 ± 2.1 days, 
P=0.008). Furthermore, the percentage of days with ineffective anticoagulation therapy 
was signficantly lower in the enoxaparin group than in the UH group (11.9 ± 20.8 versus 
43.2 ± 27.3 %, P=0.004) 
Conclusions: Low molecular weight hepadn (enoxapadn) is superior to unfractionated 
heparin for achieving more rapid and constant effective anticoagulation therapy in chron- 
ically anticoagu[atad patients prior to cardiac catheterization. 
1106-81 Interference With Point-of-Care INR De~erminatlons: 
Effect of Heparin and Low Molecular Weight Heparin on 
Multiple Point-of-Care Coagulometers 
Alan K. Jacobson, Myra Petarson, Tiffany Gunneman, Phil Ng, James Westengard, 
Lvnne Ruvbalid, Loma Linda VA Medical Center, Loma Linda, California, Loma Linda 
Universi~ Loma Linda, California. 
Background: The increased use of low molecular weight heparin preparations has 
occurred at the same time that point-of-care (POC) prothrombin time testing by patients 
and professionals has increased, raising concerns as to the accuracy of POC INR deter- 
minations in patients receiving low molecular weight heparin. 
Methods: To evaluate the magnitude of interference, 60 patients on chronic warfadn ther- 
apy underwent baseline INR testing involving the simultaneous dosing of 24 POC INR 
devices representing 10 unique coagulometer technologies from 4 companies (Roche, 
International Technidyne, Avocet, Lifescan). Patients then received a single therapeutic 
intensity dose of subcutaneous hepadn, enoxaparin, daltepadn, or tinzaparin and under- 
went repeat INR testing on all devices at one and three hours after administration result- 
ing in 40 subsets of devices and heparin preparations for evaluation. 
Results: Baseline INR values ranged from 1.3 to 5.4 and significant elevations were seen 
by one hour which increased further by throe hours. The average INR increase 3 hours 
post dose for enoxaparin was 0.35 INR, 0.46 INR for unfractionated heperin, 0.72 INR 
for daltepedn and 1.11 INR for tinzapadn. However, the effect on individual coagulome- 
ters was also quite variable (see table). 
Conclusion: There is potential for clinically significant interference in INR determinations 
obtained by POC devices in the presence of heparin preparations in the first several 
hours following subcutaneous administration. 
Magnitude end Frequency of INR Shift 
Amount of INR Shift From 0.0- 0.25 0.26- 0.50 0.51 - 0.75 0.76- t.00 >f.00 
Baseline 
Number of Systems 10 11 5 5 10 
1106-82 Magnitude of INR Variation Attributable to Differences 
Between Point-of-Care Prothrombin Time Testing 
Devices 
Alan K. Jacobson. Myra Peterson, Tiffany Gunneman, Jim Westengard, Lynne Ruybalid, 
Loma Linda VA Medical Center, Loma Linda, California, Loma Linda University, Loma 
Linda, California. 
The tNR system for the reporting of the prothrombin time test was intended to minimize 
the variation in test results between different esting systems. Limitations of the INR sys- 
tem have previously been demonstrated for central lab instrumentation and reagents. 
Evaluation of INR variability due to POC device specific characteristics was undertaken 
as a substudy to a larger project evaluating heparin interference with POC INR determi- 
nations. Methods: 60 patients on chronic warfarin therapy underwent venipuncturo acqui- 
sition of a whole blood sample which was tested on 24 devices representing 10 unique 
technologies from 4 companies (Roche, International Technidyne, Avocet, Ufescan). A 
technology was classified as unique based on endpoint detection methodology, interpre- 
tation algorithm, and thromboplastin sensitivity. 
Results: Mean INR values ranged from 1.3 to 5.4 with the majority of the values (42) 
being between 2 and 3. Significant differences were seen when the INR results were 
compared across the 10 technologies represented. Even within the therapeutic range the 
variation in INR was significant in that a patient with a mean INR of 2.5 was found to have 
JACC March 6, 2002 
values distributed between 2.0 and 2.9 with the different devices. The 95% confidence 
limits around any given INR were calculated and are presented in the table. 
Conclusion: There is significant device dependent variation in INR determinations with 
different POC testing technologies that is large enough to have significant clinical impact. 
95% Confidence Limits Across Different Test Systems 
Upper Limit 1.7 2.3 2.9 3.6 4.8 
INR 1.5 2.0 2.5 3.0 4.0 
Lower Limit 1.2 1.6 2.0 2.3 3.1 
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1107-85 Simvastatin Reduces Bone Turnover in 
Hyperchoiesterolemic Subjects Independent of Its 
Effects on LDL Oxidation and Inflammatory Markers 
Robert S. Rosenson, Craig B. Langman, Christine C. Tangney, Ellen R. Brooks, Thomas 
Parker, Daniel Levine, Bruce Gordon, Northwestern University Medical School, Chicago, 
Illinois, The Rogosin Institute, New York, New York. 
Objective: Inflammation has been recognized as a common mechanism underlying 
pathologic bone resorption and vascular calcification. Retrospective studies indicate that 
statins reduce bone fracture and coronary calcification. We investigated the effects of 
short-term (average of 7 and 8 weeks) statin therapy on (1) serum bone markers (bone 
specific alkaline phosphatase [BAP], osteocalcin [OC], and type I collagen N-telopeptide 
cresslinks [NTX]), and (2) their relationships to changes in oxidized LDL and selected 
inflammatory markers (soluble tumor necrosis factor receptors 1 and 2 [TNF R1 and R2], 
high-sensitivity CRP [hs-CRP]. 
Methods: 63 (M/F 40/23) healthy nonsmoking adults (mean ± SD, aged 51.0±8.0 y; BMh 
28.5±5,3 kg/m 2) with LDL-C between 130-189 mg/dL were randomized and treated for 8 
weeks with placebo (n=17), pravastatin 40 mg/d (n=15), simvastatin 20 mg/d (n=14) or 
simvastatin 60 mg/d (n=l 7). Fasting blood samples were acquired twice at baseline, and 
twice at study completion. 
Results: Statin therapy reduced serum BAP (group by time interaction, p= 0.004). Spe- 
cifically, simvastatin 60 mg reduced BAP (-2.3 U/L, p=0.04), whereas no change was 
seen with simvastatin 20 mg (-0.08 U/L, p =0,71), pravastatin (+0.51 U/L, p=0.21) or pla- 
cebo (0.37 U/L, p=0.51). Change in BAP (by one-way ANOVA with Student-Neuman 
Keuls test) in the simvastatin 80 mg group was different from the other treatment groups 
(p<0.05). The changes in BAP remained significant after adjustment for age, gender, and 
BMI. No significant differences were seen in OC or NTX. Reductions in LDL-C correlated 
with reductions in BAP (rho=0.25, p=0.05) across treatment groups. Statin therapy 
reduced LDL oxidative susceptibility (p = 0,014); however sTNF R1 and R2 and hs-CRP 
were unchanged. Reduction in BAP was not correlated with changes in oxidized LDL, or 
selected inflammatory markers. 
Conclusions: Short-term use of high-dose simvastatin lowers the Level of the serum 
bone marker BAP, suggestive of reduced bone turnover. The beneficial effects of high- 
dose simvastatin were unrelated to changes in LDL oxidation or certain inflammatory 
pathways. 
1107-86 In Vivo Effects of Atorvastatin on Bone Metabolism Is 
Vitamin D-Dependent 
Kou!i Kaiinami. Noboru Takekoshi, Shinobu Matsui, Hiroichi Tsugawa, Seiyu Kanemitsu, 
Bhinji Okubo, Kanazawa Medical Universi~ Uchinada-machi, Japan. 
Background: Some studies reported the significant association between statin therapy 
and reduced risk of fracture or increased bone mineral density. However, others failed to 
find this association, and clinical evidence potentially related to its mechanism has not 
been reported. 
Methods: To find the clinical variables to predict the effects of statin therapy on bone 
metabolism, we enrolled 34 patients (mean age 52 years) with heterozygous familial 
hypercholesterolemia in prospective 24-week treatment with 40 rag/day of atorvastatin. 
Serum levels of bone specific alkaline phosphatase (BALP) and osteocalcin (OC) were 
determined as bone formation marker, and urine collagen type 1 crosslinked N-telopep- 
tide (NTx) levels as bone resorption marker, in addition to serum levels of parathyroid 
hormone and 1.25(OH)2 vitamin D3 (VitD). 
Results: After discontinuation of any lipid-modifying therapy for more than 4 weeks, ator- 
vastatin 40 mg/day treatment produced 40% (345 to 208 mg/dl) and 49% (267 to 136 rag/ 
dl) reduction in total and LDL cholesterol levels, and 10% increase (51 to 56 mg/dl) in 
HDL cholesterol level, respectively. As a whole study group, none of examined markers 
showed significant alterations during treatment. However, in 14 subjects with higher VitD 
levels (>50 pg/mL) before treatment, significant increase of BALP (22.4 to 26.6 U/L) and 
small decrease of NTx (37.6 to 35.0 nMCBE/ml) were observed, whereas remaining 20 
subjects with lower VitD levels did not. PTH levels did not produce significant effects on 
alterations of markers during treatment. 
Conclusion: In vivo effects of atorvastatin on bone metabolism appears to be vitamin D- 
dependent. 
1107-87 Maximal Lipid Lowering Therapy Decreases Calcified 
Plaque Volume and Increases Calcified Plaque Density 
Udo Hoffmann, Kurt Dertler, Martin Haas, Alfred Stadler, Thomas J. Brady, Karam 
Kostner, General Hospital and University of Vienna, Vienna, Austria, Massachusetts 
General Hospital and Harvard Medical School, Boston, Massachusetts. 
Background: Coronary artery calcification is closely related to the history of elevated 
blood lipoprotein levels. We investigated the long term effect of maximal lipid lowering in- 
tervention on calcified coronary plaque characteristics in patients with familial hypercho- 
lesterolemia (FH) using computed tomography (CT). 
Methods: Heterozygote FH patients (n=8, mean age: 46_+7.6 years) were studied over a 
time period of 29 months. Patients underwent regularly LDL- apheresis (n=101_+21) and 
received Atorvastatin (80mg/daily). Blood lipopretein levels were measured at baseline 
1106-83 Antiplatelet Effects of Angiotensin Converting Enzyme 
Inhibitora Compared with Aspirin and Clopidogrel: A 
Pilot Study Using Whole Blood Aggregometry 
Dirk Skowasch, Melanie Schneider, Ren~ Andri~, Berndt L~dedtz, Gerhard Bauriedel. 
Department of Cardiology, University of Bonn, Bonn, Germany, 
Background: Platelet activation and subsequent aggregation play a key role in complica- 
tions and progression of atherosclerosis. While specific antiptatelet agents work as well- 
established, effective components in secondary prevention, recent clinical trials showed 
a decrease in cardiovascular events also for angiotensin converting enzyme (ACE) inhib- 
itors. Therefore, in the present study, we sought to assess the coagulative activity of car- 
diovascular patients grouped for treatment with either ACE inhibitors, aspirin, clopidogrel/ 
aspirin or none of these medications. 
Methods: Blood samples from 223 cardiovascular patients were analyzed by whole- 
blood aggregometry. Platelet aggregation was determined by the increase in impedance 
across paired electrodes in response to the aggregatory agents ADP and collagen, resp. 
These data were regarded for presence/absence of ACE inhibition or antithrombotic 
medication. 
Results: The central finding was that platelet aggregation was attenuated by ACE inhibi- 
tors as well as by either aspirin or clopidogrel/aspirin, indicated by a lower impedance 
increase compared to no medication. With ACE inhibition, platelet aggregation 
decreased by 36% (p=0.04) following ADP induction. No significant antithrombotic effect 
was seen with aspirin alone (34%; p=0.10), while decrease in ADP induced platelet 
aggregation was extensive with clopidogrel/aspirin (90%; p=0.001 ). After collagen induc- 
tion, there was a trend to reduced platelet aggregation with ACE inhibitor therapy (14%; 
p=0.20), whereas inhibition with aspirin was 20% (p=0.02) and that with clopidogrel/aspi- 
rin 31% (p=0.04) compared to untreated participants. 
Conclusions: These ex vivo data on whole-blood aggrogomatry provide direct evidence 
for ACE inhibitors to decrease platelet aggregation, while confirming aspirin and clopi- 
dogrel as established antithrombotics. Antiaggregatory effects with ACE inhibition may 
contribute to the beneficial influence of this drug class on major clinical, cardiovascular 
endpoints and offer an important herapeutic option in case of aspirin/clopidogrel intoler- 
ance. 
1106-84 The Effect of Drugs Which Are Known Inducers and 
Inhibitors of Human Cytochrome P450 3A on the 
Platelet Inhibitory Activity of Clopidogrel 
Wei C. Lau. Lucy Waskell, Paul B. Watkins, Charlene Neer, David Carville, Kirk E. Guyer, 
Kevin Horowitz, Eric R. Bates, University of Michigan Health System, Ann Arbor, 
Michigan, Indiana University, South Bend, Indiana. 
Background: Clopidogrel is a prodrug, which is converted to an active drug in the liver by 
cytochreme P450 (CYP). The metabolite forms a disulfide bond with the platelet ADP 
receptor, P2cyc. Platelets with a modified receptor are defective in their ability to aggre- 
gate. Two studies were undertaken to determine whether the most abundant human 
CYP, 3A4 activates clopidogrel. 
Methods: Study 1. Twenty volunteers had platelet aggregation measured with ADP ago- 
nist (Plateletworks TM) at baseline and after 6 days of clopidogrel (75 mg). After a 2 week 
washout period, erythromycin (250 mg qid), a CYP3A4 inhibitor, and rifampin (300 mg 
bid), a CYP3A4 inducer, were each given to 10 volunteers concomitant with ctopidogrel. 
Platelet aggregation was measured at baseline and 6 days. Study 2. Clopidogrel (450 
mg) was given to 5 volunteers and platelet aggregation was measured at baseline and 4 
hours. Two weeks later, troleandomycin (500 mg), the most potent CYP3A4 inhibitor, and 
clopidogret (450 mg) were both given. Platelet aggregation measurements were 
repeated at baseline and at 4 hours 
Results: Study 1. Erythromycin increased platelet aggregation form 48% to 59% 
(p=0.005). Rifampin decreased platelet aggregation from 55% to 33% (p=0.001). Study 
2. Clopidogrel initially reduced platelet aggregation from 93% to 50% (p=0.02). An eryth- 
romycin breath test showed that the addition of troleandomycin completely inhibited 
CYP3A4 activity: platelet aggregation was reduced from 90% to 80% (p=NS). 
Conclusion: These data are consistent with the hypothesis that CYP3A4 in humans 
mediates the conversion of clopidogrel to an active drug. Therefore, clopidogrel will be 
susceptible to drug interactions with the numerous medications that are inducers or 
inhibitors of CYP3A4. 
